2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2159

Pachymeningitis in Rheumatic Disease

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2467

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2604

Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2241

Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2224

Parkinson’s Disease and Risk of Fractures : A Meta Analysis of Cohort Studies

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2257

Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2256

Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2388

Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2247

Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2539

Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2151

Patient Reported Outcomes and Factors Predicting Clinical Disease Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2212

Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2313

Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2702

Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2260

Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].